Alkermes

News

Graphic of man flying a white flag against a teal background

Lundbeck bows out of bidding war for Avadel

Lundbeck won't raise its offer to buy Avadel any further, clearing the way for the sleep disorder specialist to complete a merger with Alkermes.

News

Alkermes offers more for Avadel after Lundbeck bid

Alkermes has been forced to raise its offer for narcolepsy drug developer Avadel Pharma, after a rival bid from Lundbeck was deemed superior.

News

Lundbeck makes bid for Avadel, trying to displace Alkermes

Another pharma M&A fight has broken out, with Lundbeck outbidding Alkermes in an attempt to take control of Avadel Pharma and its narcolepsy product.

News

Alkermes breaks new ground in narcolepsy with orexin drug

Alkermes' alixorexton is the first orexin 2 receptor agonist to show efficacy in phase 2 trials involving patients with both main narcolepsy subtypes.

News

Alkermes bets $2.1bn on Avadel and its narcolepsy drug

Alkermes will buy Avadel Pharma and its fast-growing narcolepsy drug Lumryz in a deal valued at up to $2.1 billion.

News

Alkermes may separate oncology business, says CEO

Alkermes has said it is considering a spin-out of its cancer business into an independent, publicly-traded company, retaining its traditional focus on neurosciences.

Lundbeck bows out of bidding war for Avadel

Alkermes offers more for Avadel after Lundbeck bid

Lundbeck makes bid for Avadel, trying to displace Alkermes

Alkermes breaks new ground in narcolepsy with orexin drug

Alkermes bets $2.1bn on Avadel and its narcolepsy drug

Alkermes may separate oncology business, says CEO

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Alkermes

Editor's Picks